乌布妥昔单抗、乌姆布拉利塞与伊布替尼联合治疗慢性淋巴细胞白血病和非霍奇金淋巴瘤患者的耐受性与活性:一项1期剂量递增和扩展试验
该研究为在美国五中心开展的开放标签1期剂量递增和扩展试验,评估乌布妥昔单抗、乌姆布拉利塞与伊布替尼三联方案治疗晚期B细胞恶性肿瘤。46例患者中37例(84%)达到总体缓解,未达到乌姆布拉利塞最大耐受剂量,常见不良事件为腹泻、疲乏和输注相关反应;作者认为该三联方案似乎可耐受且具鼓舞活性,需进一步研究。
要点
- 在46例可评估患者中,37例(84%)达到总体缓解(完全或部分缓解)。
- 乌姆布拉利塞最大耐受剂量未达到,扩展期推荐剂量为乌姆布拉利塞800 mg每日一次口服联合伊布替尼及乌布妥昔单抗。
- 常见任何级别不良事件为腹泻(59%)、疲乏(50%)和输注相关反应(43%),3-4级不良事件以中性粒细胞减少(22%)和蜂窝织炎(13%)最常见。
核心结论
- 乌布妥昔单抗、乌姆布拉利塞与伊布替尼联合方案在晚期慢性淋巴细胞白血病和B细胞非霍奇金淋巴瘤中似乎可耐受,并伴有鼓舞活性的表现。
- 作者认为该三联方案需在未来研究进一步探讨,以增进对这种新型无化疗三联方案在这类癌症管理中作用的理解。
研究设计与样本
- 开放标签1期剂量递增和扩展研究,在美国五个中心开展。
- 纳入年龄18岁及以上、组织学确诊淋巴细胞白血病或复发/难治B细胞非霍奇金淋巴瘤、有可测量病灶、器官功能充足、东部协作肿瘤组(ECOG)体能状态≤2的患者。
- 排除已知中枢神经系统淋巴瘤、活动性乙型或丙型肝炎感染或HIV患者。
- 剂量递增队列按标准3×3设计,28天为一周期,乌姆布拉利塞口服递增剂量(400、600或800 mg),乌布妥昔单抗静脉固定900 mg,伊布替尼口服固定剂量(慢性淋巴细胞白血病420 mg;B细胞非霍奇金淋巴瘤560 mg),直至疾病进展或不耐受。
- 剂量扩展阶段给予由剂量递增阶段确定的推荐剂量;主要终点为安全性、剂量限制性毒性和乌姆布拉利塞与乌布妥昔单抗及伊布替尼联合时的最大耐受剂量。
主要发现
- 2014年9月2日至2017年11月6日共入组46例患者:剂量递增队列24例(慢性淋巴细胞白血病或小淋巴细胞淋巴瘤14例;B细胞非霍奇金淋巴瘤10例),剂量扩展队列22例(慢性淋巴细胞白血病或小淋巴细胞淋巴瘤9例;B细胞非霍奇金淋巴瘤13例)。
- 46例患者至少接受一剂研究药物;乌姆布拉利塞最大耐受剂量未达到。
- 扩展期推荐剂量为乌姆布拉利塞800 mg每日一次口服联合伊布替尼每日一次口服及乌布妥昔单抗900 mg静脉给药(第1周期第1、8、15天,第2-6周期第1天,第9和12周期第1天)。
- 44例可评估患者中37例(84%)达到总体缓解(完全或部分缓解)。
- 任何级别不良事件最常见为腹泻(27例[59%])、疲乏(23例[50%])、输注相关反应(20例[43%])、头晕(17例[37%])、恶心(17例[37%])和咳嗽(16例[35%]);3-4级不良事件以中性粒细胞减少(10例[22%])和蜂窝织炎(6例[13%])最常见,经处理可管理。
临床怎么用
- 作者认为该三联方案似乎可耐受,并在晚期慢性淋巴细胞白血病和B细胞非霍奇金淋巴瘤中伴有鼓舞活性。
- 作者指出该三联方案需在未来研究中进一步探讨。
局限性
- 作者结论指出该三联方案将需要在未来研究中进一步探讨,以增进对这种新型无化疗三联方案在这类癌症管理中作用的理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies. METHODS: We did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Eligible patients were aged 18 years or older with histologically confirmed lymphocytic leukaemia or relapsed or refractory B-cell non-Hodgkin lymphoma, had measurable disease, adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Patients with known CNS lymphoma, active hepatitis B or C infection, or HIV were excluded. In the dose-escalation cohort, patients were treated in cycles of 28 days with escalating doses of oral umbralisib (400, 600, or 800 mg) and fixed doses of intravenous ublituximab (900 mg) and oral ibrutinib (420 mg for patients with chronic lymphocytic leukaemia; 560 mg for patients with B-cell non-Hodgkin lymphoma) in a standard 3 × 3 design until disease progression or intolerance. In the dose-expansion phase, patients were given the recommended dose of the drug combination as determined from the dose-escalation phase. The primary endpoints were safety, dose-limiting toxicities, and the maximum tolerated dose of umbralisib, when given in combination with ublituximab and ibrutinib. Safety was assessed in patients who received at least one dose of study drug; activity was assessed in all patients who had at least one post-treatment efficacy measurement. The study is ongoing but no longer recruiting patients. This trial is registered with ClinicalTrials.gov, number NCT02006485. FINDINGS: Between Sept 2, 2014, and Nov 6, 2017, we enrolled 46 patients: 24 in the dose-escalation cohort (n=14 chronic lymphocytic leukaemia or small lymphocytic lymphoma; n=10 B-cell non-Hodgkin lymphoma) and 22 in the dose-expansion cohort (n=9 chronic lymphocytic leukaemia or small lymphocytic lymphoma; n=13 B-cell non-Hodgkin lymphoma). 46 patients received at least one dose of study drug. The maximum tolerated dose of umbralisib was not reached. The recommended dose for the dose-expansion phase was umbralisib 800 mg orally once daily plus ibrutinib orally once daily and intravenous ublituximab 900 mg administered on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6, and on day 1 of cycles 9 and 12. 37 (84%) of 44 patients achieved an overall response (complete or partial response). The most common any-grade adverse events were diarrhoea (n=27 [59%]), fatigue (n=23 [50%]), infusion-related reaction (n=20 [43%]), dizziness (n=17 [37%]), nausea (n=17 [37%]), and cough (n=16 [35%]). Grade 3-4 adverse events were manageable with the most common being neutropenia (n=10 [22%]) and cellulitis (n=6 [13%]). Serious adverse events occurred in 11 (24%) of 46 patients and included rash (n=2 [4%]), pneumonia (n=2 [4%]), atrial fibrillation (n=2 [4%]), sepsis (n=2 [4%]), abdominal pain (n=1 [2%]), syncope (n=1 [2%]), cellulitis (n=1 [2%]), pneumonitis (n=1 [2%]), headache (n=1 [2%]), lung infection (n=1 [2%]), skin infection (n=1 [2%]), pleural effusion (n=1 [2%]), pericardial infusion (n=1 [2%]), upper gastrointestinal bleeding (n=1 [2%]), diarrhoea (n=1 [2%]), and weakness (n=1 [2%]). No deaths related to adverse events occurred. INTERPRETATION: The combination of ublituximab, umbralisib, and ibrutinib seems to be tolerable and is associated with encouraging activity in advanced chronic lymphocytic leukaemia and B-cell non-Hodgkin lymphoma. This triplet combination will require further investigation in future studies to improve understanding of this novel, chemotherapy-free triplet combination in the management of these cancers. FUNDING: TG Therapeutics.
引用
- Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019. PMID: 30709431. doi:10.1016/S2352-3026(18)30216-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。